期刊文献+

大肠癌治疗中EGFR耐药相关分子 被引量:4

EGFR resistance related molecules in the therapy of colorectal cancer
下载PDF
导出
摘要 随着医学分子生物学技术的发展和对大肠癌分子发病机制的深入研究,以表皮生长因子受体(epidermal growth factor receptor,EGFR)为靶点的分子靶向治疗在大肠癌的治疗中作用显著。其中,以西妥昔单抗和帕尼单抗为代表的抗EGFR单抗为大肠癌患者带来了福音,EGFR过表达的患者对EGFR单抗治疗敏感、疗效显著,但无论近期疗效如何,患者最终都不可避免的产生耐药性及病情进展。因此,了解抗EGFR单抗耐药机制有利于指导大肠癌患者的临床治疗。
作者 王铭 张丽华
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2017年第3期328-331,共4页 Chinese Journal of Cancer Biotherapy
  • 相关文献

参考文献2

二级参考文献52

  • 1Fang-Hua Li,Zhuang-Hua Li,Hui-Yan Luo,Miao-Zhen Qiu,Yu-Hong Li,Rui-Hua Xu,State Key Laboratory of Oncology in Southern China,Department of Medical Oncology,Sun YatSen University Cancer Center,Guangzhou 510060,Guangdong Province,China Fang-Hua Li,Department of Medical Oncology,Shengli Oil Field Central Hospital,Dongying 257034,Shandong Province,China Lin Shen,Department of GI Oncology,Peking University School of Oncology,Beijing Cancer Hospital and Institute,Beijing 100142,China Hui-Zhong Zhang,State Key Laboratory of Oncology in Southern China,Department of Pathology,Sun Yat-Sen University Cancer Center,Guangzhou 510060,Guangdong Province,China.Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer[J].World Journal of Gastroenterology,2010,16(46):5881-5888. 被引量:9
  • 2Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Globalcancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID:21296855 DOI: 10.3322/caac.20107].
  • 3Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancerstatistics, 2009. CA Cancer J Clin 2009; 59: 225-249 [PMID:19474385 DOI: 10.3322/caac.20006].
  • 4Alberts SR, Wagman LD. Chemotherapy for colorectal cancer livermetastases. Oncologist 2008; 13: 1063-1073 [PMID: 18838438DOI: 10.1634/theoncologist.2008-0142].
  • 5Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA CancerJ Clin 2015; 65: 5-29 [PMID: 25559415 DOI: 10.3322/caac.21254].
  • 6Centers for Disease Control and Prevention. United StatesCancer Statistics: US Cancer Statistics Working Group, 2013.Available from: URL: http://www.cdc.gov/uscs.
  • 7Van Cutsem E, K-hne CH, Hitre E, Zaluski J, Chang Chien CR,Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK,Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J,Rougier P. Cetuximab and chemotherapy as initial treatment formetastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417[PMID: 19339720 DOI: 10.1056/NEJMoa0805019].
  • 8Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H,Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, ChauI, Van Cutsem E. Cetuximab monotherapy and cetuximab plusirinotecan in irinotecan-refractory metastatic colorectal cancer. NEngl J Med 2004; 351: 337-345 [PMID: 15269313 DOI: 10.1056/NEJMoa033025].
  • 9Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, BarugelM, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F,Kocákova I, Ruff P, B-asińska-Morawiec M, -makal M, CanonJL, Rother M, Oliner KS, Wolf M, Gansert J. Randomized, phaseIII trial of panitumumab with infusional fluorouracil, leucovorin,and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-linetreatment in patients with previously untreated metastatic colorectalcancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705 [PMID:20921465 DOI: 10.1200/JCO.2009.27.4860].
  • 10Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, HotkoY, André T, Chan E, Lordick F, Punt CJ, Strickland AH, WilsonG, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, CollinsS, Oliner KS, Rong A, Gansert J. Randomized phase III studyof panitumumab with fluorouracil, leucovorin, and irinotecan(FOLFIRI) compared with FOLFIRI alone as second-line treatmentin patients with metastatic colorectal cancer. J Clin Oncol 2010; 28:4706-4713 [PMID: 20921462 DOI: 10.1200/JCO.2009.27.6055].

共引文献20

同被引文献35

引证文献4

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部